Oncopeptides AB (STU:OND) Total Equity : €4.72 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB Total Equity?

Oncopeptides AB's total equity for the quarter that ended in Dec. 2024 was €4.72 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Oncopeptides AB Total Equity Historical Data

The historical data trend for Oncopeptides AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Total Equity Chart

Oncopeptides AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Equity

Get a 7-Day Free Trial

56.70

20.53

26.77

5.08

4.72

Oncopeptides AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Equity	Get a 7-Day Free Trial															5.08	-0.75	17.09	11.95	4.72

Oncopeptides AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Oncopeptides AB's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	21.229	-	16.51
	=	4.72

Oncopeptides AB's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	21.229	-	16.51
	=	4.72

Oncopeptides AB Total Equity Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (STU:OND) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden 0RN4:UK OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.